Role of PRMT1 and PRMT5 in Breast Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168854 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sébastien Martinez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, F-69000 Lyon, France. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Breast Neoplasms, Repressor Proteins. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation de France, Fondation Arc, Fondation ARC Cancer.
Abstract (Originalsprache)
Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage breast cancer is curable in ~70–80% of patients, while advanced metastatic breast cancer is considered incurable with current therapies. Breast cancer is a highly heterogeneous disease categorized into three main subtypes based on key markers orientating specific treatment strategies for each subtype. The complexity of breast carcinogenesis is often associated with epigenetic modification regulating different signaling pathways, involved in breast tumor initiation and progression, particularly by the methylation of arginine residues. Protein arginine methyltransferases (PRMT1-9) have emerged, through their ability to methylate histones and non-histone substrates, as essential regulators of cancers. Here, we present an updated overview of the mechanisms by which PRMT1 and PRMT5, two major members of the PRMT family, control important signaling pathways impacting breast tumorigenesis, highlighting them as putative therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, F-69000 Lyon, France.
- CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, F-69000 Lyon, France.
- Oncology Department, Centre Leon Bérard, F-69008 Lyon, France.
ORCID-Profile: Stéphanie Sentis, Olivier Trédan, Muriel Le Romancer
Förderung
- Fondation de France
- Fondation Arc
- Fondation ARC Cancer
- Centre Léon Bérard
- ITMO Cancer of Aviesan
- INSERM
Zitieren
APA
Martinez, S., Sentis, S., Poulard, C., Trédan, O., & Le Romancer, M. (2024). Role of PRMT1 and PRMT5 in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168854
Vancouver
Martinez S, Sentis S, Poulard C, Trédan O, Le Romancer M. Role of PRMT1 and PRMT5 in Breast Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168854
BibTeX
@article{Martinez2024,
author = {Martinez, Sébastien and Sentis, Stéphanie and Poulard, Coralie and Trédan, Olivier and Le Romancer, Muriel},
title = {Role of PRMT1 and PRMT5 in Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168854}
}
EUVIMED